The effects of doxycycline treatment on inflammation and endothelial function in advanced atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23404

Enrollment

Registered

2008-07-23

Start date

2006-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis, peripheral arterial disease, inflammation, Doxycycline

Interventions

Patients were (if necessary) pre-treated with or switched to simvastatin 40 mg daily at least four weeks prior to trial start. Patients were treated with 100 mg doxycycline for four weeks

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from mild to moderate stable peripheral arterial disease who do not require carotis or femoral endarteriectomy (Fontaine IIa)

Exclusion criteria

Exclusion criteria: 1. Known hypersensitivity for tetracycline derivates 2. Patients treated with antibiotics in last 3 months for other diseases then lower urinary tract infections 3. Patients treated with immunosuppressive agents (including steroids) 4. Patients treated with fibrates 5. Patients with Diabetes Mellitus regulated with drug therapy 6. Signs of kidney or liver failure

Design outcomes

Primary

Measure	Time frame
Endothelial function	—

Secondary

Measure	Time frame
Plasma markers	—

Contacts

Public ContactJan H. Lindeman

Leiden University Medical Center Dpt. of Vascular Surgery. PO-box 9600

Lindeman@lumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)